Finding itself with nine sites across the US devoted to vaccines research and development after its mega swapping deal with Novartis, GlaxoSmithKline has decided to consolidate and create a global R&D center focused on those products in Maryland – the home of the FDA and the National Institutes of Health (NIH) and close to Washington, the seat of the US federal government.
GSK already had the state-of-the-art facility sitting in Rockville, Maryland – where the new global vaccines center will be housed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?